Who mentions $BEAM most on Surfaced?

@vulturetrades (Vulture trades 🦅) mentions $BEAM most — 12 mentions in the past 12 months.

When was $BEAM first mentioned on Surfaced?

The earliest tracked mention of $BEAM in the Surfaced archive was on Sep 3, 2025.

How many voices track $BEAM?

6 FinTwit voices have mentioned $BEAM 30 times in the past 12 months.

What kind of voices mention $BEAM most?

$BEAM is mentioned most by Long Research voices on Surfaced.

$BEAM — FinTwit mentions on Surfaced

Recent mentions

30 mentions

@adamfeuersteinJul 2, 2026 · 12:54 PM

Read here: A year after distressed buyout, what’s become of Bluebird Bio? CEO David Meek says the company, now called Genetix, is leading in sickle cell gene therapy $VRTX $CRSP $BEAM via @Jasonmmast https://t.co/PJcIWvMOcO

Open on X

@adamfeuersteinJul 2, 2026 · 12:54 PM

A year after distressed buyout, what’s become of Bluebird Bio? (Besides the new name, Genetix) Well... a lot, Genetix CEO David Meek told @Jasonmmast in a swaggering interview this week. Let me summarize Meek's proclamations: Genetix is profitable and on target to dominate the market for sickle cell gene therapies. "We’re the market leaders,” he said. “And our lead is just getting bigger," Meek said. $VRTX $CRSP Casgevy sucks, and the $BEAM effort is lame. “Let’s see if Beam even comes out, right? It’s a ghost right now,” he said. He offered no proof to back up the claims. Read more from Jason's interview with David Meek, link below.

Open on X

@investmentguru_Jul 1, 2026 · 11:38 PM

While AI continues to dominate headlines, Biotechnology is quietly becoming one of the strongest sectors in the market. Top 15 Biotechnology Stocks to Watch: $VRTX – Leader in cystic fibrosis treatments and expanding into gene-editing and rare diseases. $RVMD – Focused on precision oncology targeting RAS-driven cancers. $CRSP – Pioneer in gene-editing with approved and pipeline therapies. $NTLA – Developing in-vivo gene-editing treatments with breakthrough potential. $ABCL – AI-powered antibody discovery platform for drug development. $RXRX – Uses AI and automation to accelerate drug discovery at scale. $BEAM – Specializes in base-editing gene technology for precise DNA correction. $XENE – Focused on neurology and epilepsy-related treatments. $GH – Leader in liquid biopsy cancer diagnostics and early detection. $TWST – Produces synthetic DNA used in genomics and biotech research. $CGON – Developing immunotherapy treatments for bladder cancer and oncology. $DNLI – Focused on neurodegenerative diseases like Alzheimer’s and Parkinson’s. $IMVT – Developing therapies for autoimmune diseases using antibody technology. $ARWR – RNA interference platform targeting genetic and chronic diseases. $KRYS – Commercial-stage gene therapy company focused on rare skin disorders. These names represent the frontier of modern medicine where genetics, AI, and precision therapies are converging. As capital rotates beyond AI infrastructure, biotech is shaping up as one of the most compelling long-term opportunity sectors.

Open on X

@investmentguru_Jun 28, 2026 · 11:57 AM

The market just handed us a masterclass in thesis validation. The top performers of 2026 aren’t random. They’re a roadmap. Memory $SNDK. $MU. $WDC. Three names. One theme. The world needed storage and these companies delivered. The market rewarded them accordingly. Semiconductors $AXTI. $AAOI. $MRVL. $ARM. $INTC. $CRDO. $SMCI. $AMD. The silicon backbone of the AI buildout showed up — and showed out. Semiconductor Equipment & Testing $AEHR. $KLAC. $ONTO. $COHU. Because you can’t build the chips without testing them first. The enablers always get paid eventually. AI Infrastructure $DELL. $NBIS. $PENG. $CRWV. $IREN. $CLS. The picks-and-shovels layer printed. Clean Energy $BE $OKLO. $CEG. $FLNC. quietly joined the leaders board. The energy transition isn’t a story for tomorrow — it’s already in the returns. Synthetic Biology $TWST. $BEAM. DNA writing meets AI. One of the most underappreciated convergence plays on the board. Cloud & Developer Infrastructure $DOCN. $CFLT. $NET. $GTLB. Profitable. Growing. Underowned. The quiet compounder that snuck onto the leaderboard. ➡️ Memory ➡️ Semis & Equipment ➡️ AI Infrastructure ➡️ Clean Energy ➡️ Synthetic Biology ➡️ Cloud Infrastructure The Silicon-to-Substation thesis didn’t just play out on paper. It played out in portfolios. The leaders of the next leg are already hiding in plain sight. Not financial advice.

Open on X

@vulturetradesJun 24, 2026 · 2:42 PM

$BEAM looks A+ don’t miss it

Open on X

@cobraalertsJun 24, 2026 · 2:41 PM

$BEAM 45 CALL 7/17 @ here 🐍🚨

Open on X

@vulturetradesJun 24, 2026 · 2:41 PM

$BEAM 45 Call 7/17 here 🚨

Open on X

@cobraalertsJun 24, 2026 · 2:41 PM

$BEAM 45 CALL 7/17 @ .50 🐍🚨🚨

Open on X

@vulturetradesJun 24, 2026 · 2:41 PM

High Confidence 🚨 $BEAM 45 Call 7/17 at 0.50

Open on X

@vulturetradesJun 24, 2026 · 2:40 PM

$BEAM 45 Call 7/17 at 0.50 🚨

Open on X

@cobraalertsJun 24, 2026 · 2:40 PM

HIGH CONFIDENCE $BEAM 45 CALL 7/17 @ .50 🐍🚨

Open on X

@cobraalertsJun 24, 2026 · 2:40 PM

$BEAM 45 CALL 7/17 @ .50 🐍🚨

Open on X

@investmentguru_Jun 21, 2026 · 2:24 PM

The Next Trillion-Dollar Wave Isn’t in Semiconductors. It’s in Your Bloodstream. Everyone’s watching chips, NeoCloud, and power. Meanwhile, AI is quietly rewiring healthcare from reactive to predictive — and almost nobody is positioned for it. Healthcare is moving through the same kind of capital cycle we’ve mapped in AI infrastructure: a foundational layer (genomics) enabling a diagnostic layer (AI-read data) enabling a delivery layer (personalized treatment) enabling a behavioral layer (digital therapeutics that keep patients engaged). Four layers, four sets of plays. 1. Gene Therapies — The Foundational Layer This is the “silicon” of biotech: rewrite the underlying code, fix the disease at the source. 2026 has been a genuine inflection point — the FDA has leaned into faster, more flexible review pathways for cell and gene therapies, and the pipeline is converting. •$QURE (uniQure) — surged sharply this month on a major gene therapy advancement; a name riding the regulatory tailwind directly •$RGNX (REGENXBIO) — AAV gene therapy platform with a PDUFA decision already through in February and multiple late-stage pivotal readouts through 2026; partnered with AbbVie on what could be the first gene therapy for a non-rare disease (wet AMD) •$NTLA (Intellia) / $CRSP (CRISPR Therapeutics) / $BEAM (Beam Therapeutics) — the core gene-editing complex; CRSP remains range-bound despite holding the world’s first approved CRISPR therapy, which is exactly the kind of “stuck but structurally important” setup worth tracking 2. AI-Assisted Diagnostics — The Inference Layer This is where AI infrastructure spend actually shows up as patient outcomes. The model: ingest multimodal data (genomic, imaging, clinical), run inference, return an actionable diagnosis faster than a human panel. •$TEM (Tempus AI) — the clearest pure-play. Q1 2026 revenue +36% YoY to $348M, diagnostics revenue +35%, MRD test volume up ~500% YoY, full-year guidance raised to $1.59–1.60B. This is the diagnostics version of a NeoCloud growth curve •$PACB (Pacific Biosciences) — sequencing infrastructure, the “memory layer” underneath every genomic diagnostic •$BFLY (Butterfly Network) — point-of-care imaging, AI-assisted ultrasound, democratizing diagnostic access 3. Precision Medicine — The Targeting Layer Where genomics and diagnostics converge into “right drug, right patient, right time.” •$PRAX (Praxis Precision Medicines) — CNS precision neuroscience, translating genetic epilepsy insights into targeted therapies, multiple readouts ahead in 2026 •$RGNX again earns a mention here — its retinal and Duchenne programs are precision-targeted by genetic subtype, not blanket indications •Watch the AbbVie/Gilead-style partnership pattern — Big Pharma is increasingly outsourcing precision targeting to smaller platform companies rather than building in-house, which is where the asymmetric upside sits 4. Digital Therapeutics — The Engagement Layer The layer that keeps patients adherent and reduces cost-of-care between clinical touchpoints — software as the prescription. •$HIMS (Hims & Hers) — already a long-term holding in the core portfolio; consumer-facing digital health at scale •$GDRX (GoodRx) — Pharma Direct revenue +82% YoY in Q1 2026, a real signal that the direct-to-consumer medication/therapeutics rail is accelerating •$TDOC (Teladoc) — legacy name still worth tracking as the digital-care distribution layer consolidates The framework, simply: Genomics writes the code → AI reads the code → precision medicine targets the code → digital therapeutics keeps you compliant with the fix. Same wave structure as chips → memory → photonics → energy, just running through biology instead of silicon. This sector moves on binary catalysts (PDUFA dates, trial readouts) rather than smooth growth curves like NeoCloud — size positions accordingly and expect volatility around data releases. Not financial advice.

Open on X

@vulturetradesMay 27, 2026 · 2:28 PM

$BEAM contracts undervalued don’t miss it

Open on X

@vulturetradesMay 27, 2026 · 2:27 PM

$BEAM 38 Call 6/18 here 🚨

Open on X

@vulturetradesMay 27, 2026 · 2:27 PM

Potential 2-3x 🚨 $BEAM 38 Call 6/18 at 1.10

Open on X

@cobraalertsMay 27, 2026 · 2:27 PM

$BEAM 38 CALL 6/18 @ 1.10 🐍🚨

Open on X

@vulturetradesMay 27, 2026 · 2:27 PM

$BEAM 38 Call 6/18 at 1.10 🚨

Open on X

@cobraalertsMay 27, 2026 · 2:07 PM

$BEAM .90 to 1.30+ WOW 🐍

Open on X

@vulturetradesMay 27, 2026 · 2:07 PM

$BEAM 45% in 5 minutes 🤯 0.90 —> 1.30 Who is finding setups like this??? https://t.co/l4I4Qnckj4

Open on X

@vulturetradesMay 27, 2026 · 2:03 PM

$BEAM ripping 🚀

Open on X

@vulturetradesMay 27, 2026 · 2:00 PM

High Confidence 🚨 $BEAM 37 Call 6/18 at 0.90

Open on X

@cobraalertsMay 27, 2026 · 2:00 PM

$BEAM 37 CALL 6/18 @ .90 🐍🚨

Open on X

@vulturetradesMay 27, 2026 · 2:00 PM

$BEAM 37 Call 6/18 at 0.90 🚨

Open on X

@investmentguru_Apr 5, 2026 · 1:02 PM

The Next Big Winners: Long-Term Investment Ideas: 1. $ASTS — AST SpaceMobile Space-based cellular broadband direct to smartphones. Several mobile network providers have given the company contracted revenue obligations totaling over $1 billion, with partial service expected in late 2026 and full service in early 2027. TAM is enormous — every unconnected human on Earth. 2. $PLTR — Palantir AI + defense = unstoppable combo in this geopolitical era. Analysts project 60% revenue growth in FY2026 followed by more than 40% growth in FY2027. Government contract stickiness creates a durable moat. 3. $RKLB — Rocket Lab Commercial space infrastructure play. Launch + spacecraft manufacturing + satellite services. Beneficiary of the space economy buildout with SpaceX proving the market is real. 4. $BEAM — Beam Therapeutics Base editing gene therapy — next-gen beyond CRISPR. The company announced BEAM-304 for phenylketonuria with an IND filing expected in 2026, plus a $500 million non-dilutive financing deal. Multi-program pipeline = multiple shots on goal. 5. $LWLG — Lightwave Logic Photonics / electro-optic polymer plays — right in your wheelhouse. Chip-scale optical modulation tech that could underpin next-gen AI interconnects at speeds silicon can’t match. High risk 6. $NET — Cloudflare Delivers integrated cloud-based cybersecurity, networking and performance solutions — in an era where cyberthreats are persistent and downtime costs are significant, making it an essential partner for businesses. AI workloads are expanding the attack surface — Cloudflare wins regardless of who wins the AI race. 7. $IONQ — IonQ Quantum computing pure-play. Early innings, but quantum computing stocks have pulled back in 2026, creating a potential buying opportunity for long-term investors. Government and pharma contracts building. 5–10 year call option on a paradigm shift. 8. $TSMC — Taiwan Semiconductor The picks-and-shovels king. Full-year 2025 revenue hit $122.4B, up 35.9% over 2024, with gross margin expanding to 59.9% and diluted EPS growing 46.4%. Every AI chip runs through TSMC. 9. $PATH — UiPath Enterprise AI automation. If UiPath secures a larger share of the enterprise AI automation budget, the growth multiple could expand significantly — key catalysts include cross-sell into AI orchestration and margin improvement from large enterprise deals. Deeply discounted vs. its 2021 highs. 10. $LLY — Eli Lilly GLP-1 dominance is just beginning. Q4 2025 saw 110% revenue growth for Mounjaro and 123% growth for Zepbound, with analysts projecting 25.9% revenue growth in 2026. Obesity, diabetes, and now potential Alzheimer’s applications = multi-decade runway. Not financial advice.

Open on X

@midascabalJan 19, 2026 · 12:39 AM

Looking into gene editing stocks like $PRME $CRSP and $BEAM. Which one do you believe is the best and why?

Open on X

@investmentguru_Jan 14, 2026 · 1:54 AM

Key themes to watch: •Early Detection ( $GH, $EXAS ) : AI-driven diagnostics and liquid biopsy remain one of the fastest paths to real-world impact and revenue scalability. •Robotics & Automation ( $ISRG, $RBOT ) : Surgical automation is a long-duration growth story as hospitals push for precision, efficiency, and cost control. •Multi-omics & Genomics ( $TXG, $ILMN, $CRSP, $BEAM $TEM ) : AI + sequencing is accelerating target discovery, personalization, and next-gen therapies. •Virtual Care & Monitoring ( $TDOC, $HIMS ) : AI-driven engagement, triage, and personalization continue to reshape patient access and care delivery. •AI Drug Discovery ( $RXRX, $SDGR, $ABCL ) : Platform-based models remain volatile short term but offer asymmetric upside as pipelines mature. •Infrastructure & Enablers ( $VEEV, $DOCS, $GEHC ) : The “picks and shovels” of AI healthcare adoption.

Open on X

@investmentguru_Dec 23, 2025 · 12:49 AM

Runners Everywhere Today — Risk Is ON The market flipped the switch to full momentum mode, with speculative growth leading across the board. Capital is clearly rotating into future-facing themes, and breadth is strong. Space Stocks Explode $FJET +370.85% led the charge, followed by big moves in $SIDU +97.41%, $ASTS +14.03%, $RKLB +9.97%, $LUNR +11.71%, and strength across the entire space complex. Space is back in focus. Quantum Computing Heating Up $QBTS +20.00%, $RGTI +13.13%, $QUBT +12.86%, and $IONQ +11.10% — investors are positioning early for the next computing wave. Robotics Catch a Bid Steady accumulation in $PDYN, $SERV, $PRCT, and $MBOT shows robotics remains a core AI-adjacent theme. Batteries & Energy Storage $KULR +18.30% stood out, with continued strength in $ENVX and $ABAT as next-gen battery tech stays in demand. Drones Take Flight $UMAC +20.91% and $RCAT +14.53% reflect growing defense and commercial interest. Neoclouds & 🖥️ HPC Momentum in AI infrastructure continues: $NUAI, $WYFI, $NBIS, along with miners/HPC names like $HUT, $BITF, and $IREN pushing higher. Optics, Rare Earths & Solar From $POET to $UAMY and $RUN, multiple supply-chain and clean-energy plays moved together — a sign of broad thematic participation. Biotech Joins the Party $ABSI, $TWST, and $BEAM catching bids as risk appetite expands beyond pure tech.

Open on X

@kaizen_investorDec 22, 2025 · 9:18 PM

Biotech & Genomics is the 2nd largest growing TAM globally. Despite this potential, the sector remained stagnant in 2025. While capital flooded into AI, pharma was ignored. I expect this to change in 2026. Here are the companies on my watchlist: Metabolic & Weight Loss Leaders • $LLY (Eli Lilly): Obesity, diabetes, and Alzheimer's drugs • $NVO (Novo Nordisk): Global leader in diabetes care • $VKTX (Viking Therapeutics): Potent oral obesity therapies Surgical Robotics & Navigation • $ISRG (Intuitive Surgical): Robotic minimally invasive surgery • $PRCT (Procept BioRobotics): Robotic waterjet prostate surgery • $CLPT (ClearPoint Neuro): Precise navigation for brain surgery Gene Editing Pioneers • $NTLA (Intellia Therapeutics): In-vivo CRISPR gene editing • $BEAM (Beam Therapeutics): Precision genetic base editing • $PRME (Prime Medicine): Precise search-and-replace gene editing Diagnostic & Monitoring Tech • $DXCM (DexCom): Continuous glucose monitoring sensors • $NTRA (Natera): DNA testing for cancer/transplants • $WGS (GeneDx): Genomic diagnostics for rare diseases Specialized Biotech & Organ Care • $VRTX (Vertex): Cystic fibrosis and pain cures • $ARGX (Argenx): Novel autoimmune disease treatments • $TMDX (TransMedics): Living organ transport systems Bio-Infrastructure & Data • $VEEV (Veeva Systems): Cloud software for life sciences • $IQV (IQVIA): Clinical trial data and analytics • $TMO (Thermo Fisher): Scientific equipment and lab services • $DNA (Ginkgo Bioworks): Platform for cell programming Consumer Digital Health • $HIMS (Hims & Hers): Personalized telehealth and prescriptions

Open on X

@adamfeuersteinSep 3, 2025 · 1:48 PM

Your Wednesday AATD scorecard: $WVE down $BEAM up

Open on X

$BEAM

$BEAM

About this stock

Related stocks

Frequently asked